Haemonetics Raises Fiscal 2027 Organic Revenue Growth Outlook to 6% to 9%

Haemonetics lifted its fiscal 2027 organic revenue growth outlook Thursday, Nov. 5, 2026, after second-quarter organic revenue rose 10%, while reducing its expected adjusted operating margin expansion for the year. The new forecast sets organic revenue growth at 6% to 9%, up from 4% to 7%. The reported revenue growth range now stands at 8% to 11%, versus the prior 5% to 8%. Haemonetics projects high-single-digit organic growth in Apheresis and mid-single-digit growth in MedSurg. Its fiscal year ends April 3, 2027. Revenue for the quarter ended Sept. 26, 2026, totaled $357.8 million, a 9.3% increase from a year earlier.

Source: TokenPost